Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 5MuBV | 5MuBV54 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 54 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L, I54V, V82A | K14R, R41K, L63P, A71V, I93L |
| >5MuBV54| 62 | codons 1-99 | clone 62 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 63 | codons 1-99 | clone 63 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 64 | codons 1-99 | clone 64 PQITLWQRPIVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 65 | codons 1-99 | clone 65 PQITLWQRPIVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKAIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 66 | codons 1-99 | clone 66 PQITLWQRPIVTIRIGGQLKEALIDTGADDTVLEEMNLPGKWKPKIIGGIGGFVKVRQYD QIPVEICGHKTIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 68 | codons 1-99 | clone 68 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 69 | codons 1-99 | clone 69 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 70 | codons 1-99 | clone 70 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| 72 | codons 1-99 | clone 72 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF >5MuBV54| codons 1-99 PQITLWQRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKLIGGIGGFVKVRQYD QIPIEICGHKVIGTVLVGPTPANIIGRNLLTQLGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |